Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
RMD 
ResMed Inc (RMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/08/2026: RMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $291.8
1 Year Target Price $291.8
| 8 | Strong Buy |
| 4 | Buy |
| 6 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.94% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/08/2026 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 36.23B USD | Price to earnings Ratio 25.38 | 1Y Target Price 291.8 |
Price to earnings Ratio 25.38 | 1Y Target Price 291.8 | ||
Volume (30-day avg) 19 | Beta 0.88 | 52 Weeks Range 198.60 - 293.11 | Updated Date 01/8/2026 |
52 Weeks Range 198.60 - 293.11 | Updated Date 01/8/2026 | ||
Dividends yield (FY) 0.88% | Basic EPS (TTM) 9.78 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 27.35% | Operating Margin (TTM) 34.62% |
Management Effectiveness
Return on Assets (TTM) 14.19% | Return on Equity (TTM) 25.41% |
Valuation
Trailing PE 25.38 | Forward PE 22.83 | Enterprise Value 35692797833 | Price to Sales(TTM) 6.89 |
Enterprise Value 35692797833 | Price to Sales(TTM) 6.89 | ||
Enterprise Value to Revenue 6.79 | Enterprise Value to EBITDA 17.83 | Shares Outstanding 145966294 | Shares Floating 145054005 |
Shares Outstanding 145966294 | Shares Floating 145054005 | ||
Percent Insiders 0.51 | Percent Institutions 65.55 |
Upturn AI SWOT
ResMed Inc
Company Overview
History and Background
ResMed Inc. was founded in 1989 by Peter Farrell. Initially focused on developing continuous positive airway pressure (CPAP) devices to treat sleep apnea, the company has evolved into a global leader in connected care solutions for sleep apnea, COPD, and other chronic respiratory conditions. Key milestones include the development of the first full face mask for CPAP therapy, its IPO in 1995, and the significant expansion into digital health and remote patient monitoring.
Core Business Areas
- Sleep Apnea: Design, manufacture, and market a range of products for the diagnosis and treatment of sleep-disordered breathing, primarily sleep apnea. This includes CPAP devices, masks, ventilators, and accessories.
- Respiratory Care: Provide solutions for the management of chronic respiratory diseases such as COPD and neuromuscular respiratory conditions. This encompasses ventilators, humidifiers, and digital tools for remote monitoring and disease management.
- Digital Health Solutions: Develop and offer connected care platforms and software that enable remote monitoring, data analytics, and personalized patient management for individuals with chronic diseases. This includes solutions for improving adherence and clinical outcomes.
Leadership and Structure
ResMed is led by a seasoned executive team, with Mick Farrell serving as the Chief Executive Officer. The company operates globally with a decentralized structure that allows regional responsiveness while maintaining a unified corporate strategy.
Top Products and Market Share
Key Offerings
- AirSenseu2122 CPAP Machines: ResMed's flagship line of CPAP devices known for their user-friendly design, quiet operation, and advanced features like auto-adjusting pressure and integrated humidification. Competitors include Philips Respironics and Fisher & Paykel Healthcare.
- AirFitu2122 Masks: A comprehensive range of masks designed for comfort and effectiveness in delivering PAP therapy, including full face, nasal, and nasal pillow mask options. Competitors are largely the same as for CPAP machines, with brands like Philips Respironics and Fisher & Paykel Healthcare offering similar product lines.
- ApneaLinku2122 Air: A portable, in-home sleep testing device that helps diagnose sleep apnea. This product competes with other diagnostic solutions from companies like Philips Respironics and smaller diagnostic device manufacturers.
- ResMed AirViewu2122 & myAiru2122 App: Digital platforms for remote patient monitoring and therapy management. AirView is a cloud-based platform for clinicians, and myAir is a patient-facing app that provides therapy insights and support. This area competes with broader digital health platforms and patient engagement tools, often in conjunction with other device manufacturers.
Market Dynamics
Industry Overview
The sleep apnea and respiratory care market is characterized by a growing prevalence of chronic respiratory diseases, an aging global population, and increasing awareness of the health consequences of untreated sleep apnea. The industry is also being transformed by digital health technologies and remote patient monitoring, driving demand for connected devices and data-driven care solutions. Regulatory environments and reimbursement policies significantly influence market dynamics.
Positioning
ResMed holds a strong leadership position in the sleep apnea market, particularly in North America and Europe, due to its innovative product portfolio, strong brand recognition, and extensive distribution network. The company's strategic focus on connected care and digital health solutions provides a significant competitive advantage, enabling better patient outcomes and improved healthcare economics. Their commitment to research and development further solidifies their standing.
Total Addressable Market (TAM)
The global market for sleep apnea devices and respiratory care is substantial and growing, with estimates for the sleep apnea devices market alone projected to reach tens of billions of dollars in the coming years. ResMed is a dominant player within this TAM, with a significant market share in key product categories.
Upturn SWOT Analysis
Strengths
- Strong brand recognition and reputation in the sleep apnea market.
- Extensive global distribution network and strong customer relationships.
- Leadership in connected care and digital health solutions.
- Significant investment in research and development leading to product innovation.
- Diversified product portfolio addressing multiple chronic respiratory conditions.
Weaknesses
- Dependence on a few key product lines.
- Potential impact of increased competition from emerging players or generic products.
- Sensitivity to regulatory changes and reimbursement policies in different regions.
- Reliance on third-party suppliers for certain components.
Opportunities
- Growing global prevalence of sleep apnea and other respiratory diseases.
- Increasing adoption of telehealth and remote patient monitoring.
- Expansion into emerging markets with unmet medical needs.
- Development of new therapies and diagnostic tools for respiratory conditions.
- Potential for strategic partnerships and acquisitions to broaden offerings.
Threats
- Intensifying competition from established and new market entrants.
- Changes in healthcare policies and reimbursement rates.
- Product recalls or safety concerns impacting brand reputation.
- Economic downturns affecting healthcare spending.
- Cybersecurity risks associated with connected devices and patient data.
Competitors and Market Share
Key Competitors
- Philips Respironics (a segment of Koninklijke Philips N.V.)
- Fisher & Paykel Healthcare (FPH.NZ)
- 3B Medical Inc.
Competitive Landscape
ResMed's primary advantage lies in its strong innovation pipeline, particularly in connected care and digital solutions, which differentiates it from competitors. Philips Respironics is a significant competitor with a broad product range, though it has faced past product recall challenges. Fisher & Paykel Healthcare is strong in respiratory humidification and critical care products. The market is competitive, with pricing pressures and the need for continuous product development being key factors.
Major Acquisitions
MediScan
- Year: 2022
- Acquisition Price (USD millions): 130
- Strategic Rationale: To enhance ResMed's diagnostic capabilities for sleep and respiratory conditions and expand its digital health offering.
SomnoMed
- Year: 2024
- Acquisition Price (USD millions): 234
- Strategic Rationale: To strengthen ResMed's oral appliance therapy solutions for sleep apnea, offering a complementary treatment option to CPAP.
Growth Trajectory and Initiatives
Historical Growth: ResMed has exhibited consistent historical growth, fueled by the increasing diagnosis of sleep apnea and the expansion of its product offerings into other respiratory conditions. The company's strategic embrace of digital health has been a key driver of recent growth.
Future Projections: Analyst projections generally indicate continued revenue and earnings growth for ResMed, driven by the expanding TAM for respiratory care solutions, an aging population, and the ongoing adoption of connected health technologies. Growth is expected to be supported by both organic initiatives and potential strategic acquisitions.
Recent Initiatives: Recent initiatives include the launch of new advanced CPAP devices and masks, expansion of their digital health platforms for enhanced patient engagement and remote monitoring, and strategic acquisitions aimed at strengthening their position in complementary areas of respiratory care and digital health.
Summary
ResMed is a strong leader in the sleep apnea and respiratory care market, driven by innovation in connected care and a growing global demand for its solutions. The company exhibits consistent financial performance and a clear growth trajectory. Potential headwinds include intense competition and evolving regulatory landscapes. Continued investment in R&D and strategic acquisitions will be crucial for maintaining its market dominance.
Similar Stocks
Sources and Disclaimers
Data Sources:
- ResMed Inc. Investor Relations
- Company Annual and Quarterly Reports
- Financial News Outlets (e.g., Wall Street Journal, Bloomberg)
- Industry Analysis Reports
Disclaimers:
This analysis is based on publicly available information and is intended for informational purposes only. It does not constitute investment advice. Financial data and market share figures are estimates and subject to change. Users should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ResMed Inc
Exchange NYSE | Headquaters San Diego, CA, United States | ||
IPO Launch date 1995-06-02 | CEO & Chairman Mr. Michael J. Farrell BE, MBA, SM | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 10600 | Website https://www.resmed.com |
Full time employees 10600 | Website https://www.resmed.com | ||
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.